These findings were quite an important step for our organoruthenium compounds, because they were the first demonstration that a ruthenium complex could exert its anticancer activity with less toxicity than platinum compounds, via an original signaling pathway, the ER stress pathway, and that this complex could bypass the requirement for DNA damage and the activity of the tumor suppressor gene p53 (that is mutated in 50% of cancers) to induce cytotoxicity in cancer cells. This evidence concerns the gene TP53 and cancer.